The cost of waiting: What reaching clinical proof-of-concept sooner means for biotech cash burn

By Julie-Ann Cabana, Chief Marketing Officer, Altasciences

With close to 30 years working in the biotech and CRO industries, I have seen how drug development timelines influence a biotech company's financial position. For companies operating with finite capital, the question is not simply how much a study costs, but rather how much cash the business consumes before generating evidence that supports its next investment decision.

As programs advance toward clinical proof-of-concept (POC), companies continue funding personnel, infrastructure, research, external partners/vendors, and regulatory activities. Each additional month consumes runway, whether meaningful development progress occurs.

A biotech budgeting survey published by Pillar VC examined 12 founder-led companies and estimated average monthly cash burn at approximately $20,000 USD per employee. Although the sample was small and should not be treated as an industry benchmark, it offers a useful starting point for examining the financial implications of time.

Using that estimate, a 10-person company could consume approximately $200,000 monthly, while a 100-person organization could consume $2 million. A delay of six to 12 months in development could represent approximately $1.2 million to $24 million USD in cash-burn exposure.

These figures reflect a hypothesis, not demonstrated savings. Actual capital preserved depends on which expenditures are time-dependent, whether development activities overlap, and how spending changes when milestones are reached earlier.

Time can also influence commercial economics. According to the FDA, a new patent generally runs for 20 years from its filing date, although adjustments, extensions, and regulatory exclusivities can impact effective protection. Earlier development may preserve additional commercial opportunity, depending on the asset's intellectual property position and eventual approval timeline. 

Where drug development programs lose time

Development delays don’t always originate from the science. They can arise between R&D activities, particularly when nonclinical studies, bioanalysis, manufacturing, regulatory preparation, and clinical operations are planned sequentially across multiple providers. Contracting, technology transfers, assay readiness, clinical-supply coordination, and scheduling dependencies can extend the critical path. Individual providers may deliver successfully against their respective commitments while the overall program advances more slowly than necessary. 

McKinsey identified contracting and coordination as opportunities to reduce nonclinical development time, citing preferred CRO/CDMO supplier arrangements that reduce procurement steps and resources. In a separate analysis, McKinsey also found that technology transfers to external manufacturing partners took an average of 5.8 months longer than internal transfers, illustrating how external interfaces can extend development timelines.

A company can continue consuming capital during these intervals without necessarily generating additional evidence that increases the asset’s value. Importantly, eliminating a handoff does not automatically eliminate its associated cost. The relevant question is whether improved coordination can shorten the time to a decision-enabling milestone without introducing unacceptable scientific, operational, or regulatory risk.

The financial hypothesis: What could six months of time savings mean?

Consider a hypothetical 50-person biotech company using the survey's $20,000 monthly per-employee estimate. Its implied monthly burn would be approximately $1 million. But if the company could reach clinical POC six to 12 months earlier, it could save up to $12 million in capital. 

Fixed commitments, accelerated expenditures, additional studies, and changing headcount can alter the outcome. A credible financial assessment should compare the complete cash-flow forecasts of accelerated and conventional development plans, not simply multiply monthly burn by months saved.

The potential value also extends beyond expenditure. Earlier POC evidence may support financing, licensing, acquisition discussions, or a decision to discontinue an unsuccessful program before committing further capital.

None of these outcomes is guaranteed, but reaching an informed decision sooner can have meaningful financial implications, particularly for venture-backed companies managing runway against milestone-dependent financing.

Can integrated development change the equation?

At Altasciences, our approach is built around reducing avoidable time between development activities. The Altasciences Acceleration Platform coordinates nonclinical research, bioanalysis, manufacturing, clinical development, and regulatory planning into one workflow to potentially reduce development timelines by up to 40%. 

We accelerate timelines by identifying critical-path dependencies and determining which activities can proceed concurrently without compromising scientific quality, participant safety, or regulatory readiness. For example, clinical planning can advance alongside nonclinical assessments. Bioanalytical methods can be developed at the start, before clinical samples arrive. Manufacturing and regulatory preparations can be coordinated with anticipated study milestones.

A published Altasciences case study describes how a novel incretin-based therapeutic advanced from safety assessment to clinical POC topline results in just 22 months—more than two years ahead of industry norms–and achieved IND submission readiness around six months earlier than projected. Early data access allowed the client to unlock critical program funding to advance into human studies, further reinforcing its competitive position.

For biotech executives and investors, the broader question is worth testing: If development coordination can remove six months from the critical path, how much capital could remain available for the next milestone? The answer will differ by company, but understanding the relationship between development timelines, cash consumption, and decision-making should be central to capital-efficient drug development.

Contact the Altasciences team to explore potential opportunities to accelerate your development timelines.